Delving into the Latest Updates on SYHX-1901 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

JAK x TYK2

Action

inhibitors

Mechanism

JAK inhibitors(Janus kinase inhibitors), TYK2 inhibitors(Tyrosine-protein kinase 2 inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesOther Diseases+ [4]

Active Indication

PsoriasisAlopecia AreataVitiligo+ [7]

Inactive Indication-

Originator Organization

CSPC Ouyi Pharmaceutical Co., Ltd.

Active Organization

CSPC Ouyi Pharmaceutical Co., Ltd.

CSPC Pharmaceutical Group Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

主要目的：比较健康受试者口服不同制剂处方和规格SYHX1901片的相对生物利用度。次要目的： 1) 评估健康受试者口服不同制剂处方和规格SYHX1901片的药代动力学特征； 2) 评估健康受试者口服不同制剂处方和规格SYHX1901片的安全性和耐受性。

[Translation]

Primary objective: To compare the relative bioavailability of SYHX1901 tablets of different formulations and strengths in healthy subjects. Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of SYHX1901 tablets of different formulations and strengths in healthy subjects; 2) To evaluate the safety and tolerability of SYHX1901 tablets of different formulations and strengths in healthy subjects.

Start Date03 Mar 2025

Sponsor / Collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

NCT06562894

/ Not yet recruitingPhase 2

A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Severe Alopecia Areata

The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of severe alopecia areata.

Start Date16 Nov 2024

Sponsor / Collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

100 Clinical Results associated with SYHX-1901

Login to view more data

100 Translational Medicine associated with SYHX-1901

Login to view more data

100 Patents (Medical) associated with SYHX-1901

Login to view more data

100 Deals associated with SYHX-1901

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alopecia Areata	Phase 3	China	CSPC Pharmaceutical Group Ltd.	-
Psoriasis	Phase 3	China	CSPC Pharmaceutical Group Ltd.	-
Vitiligo	Phase 3	China	CSPC Pharmaceutical Group Ltd.	-
Nonsegmental vitiligo	Phase 2	China	CSPC Ouyi Pharmaceutical Co., Ltd.	27 May 2024
Plaque psoriasis	Phase 2	China	CSPC Ouyi Pharmaceutical Co., Ltd.	11 Apr 2023
COVID-19	Phase 1	China	CSPC Pharmaceutical Group Ltd.	23 Nov 2022
Rheumatoid Arthritis	Phase 1	China	CSPC Pharmaceutical Group Ltd.	15 Jul 2022
Systemic Lupus Erythematosus	Phase 1	China	CSPC Pharmaceutical Group Ltd.	15 Jul 2022
Hematologic Neoplasms	IND Approval	China	CSPC Ouyi Pharmaceutical Co., Ltd.	13 Jan 2025
Solid tumor	IND Approval	China	CSPC Ouyi Pharmaceutical Co., Ltd.	13 Jan 2025